DLC1 and breast carcinoma: (54) reported a higher expression of the ERBB2 gene in Caucasians when compared to AA breast cancer patients (ERBB2 mean fold change (FC) in Caucasians: 1.61 vs AAs: 0.63, p=0.012), and other genes associated with prognosis (ESR1 and GATA3), disease progression (HSPB1 and SERPINA3) and response to chemotherapy (CLDN7 and DLC1).